Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Revance Therapeutics, Inc. (RVNC)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | 471.0% | 1922.1% | 39920.6% | 3925.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Gross profit | -371.0% | -1822.1% | -39820.6% | -3825.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | 255.6% | 990.8% | 15014.8% | 1444.4% | 14274.0% | 9691.7% | 8362.7% | 4972.1% |
| Research and development | 149.4% | 820.8% | 24905.8% | 2480.6% | 30672.1% | 16793.7% | 15843.0% | 8718.0% |
| EBITDA | -327.5% | -1715.6% | -39116.2% | -3778.7% | -44285.9% | -25903.7% | -23440.7% | -13054.6% |
| Depreciation | 25.5% | 66.9% | 704.4% | 46.3% | 560.3% | 481.7% | 665.0% | 535.5% |
| EBIT | -353.1% | -1782.5% | -39820.6% | -3825.0% | -44846.2% | -26385.3% | -24105.7% | -13590.1% |
| Pre-tax income | -361.6% | -1858.5% | -38602.7% | -3823.2% | -46025.6% | -29756.7% | -24492.0% | -16422.2% |
| Income taxes | 0.0% | -0.7% | 0.0% | -80.5% | 0.0% | 0.0% | 0.0% | 0.8% |
| Net income | -361.6% | -1840.7% | -38602.7% | -3742.8% | -46025.6% | -29756.7% | -24500.0% | -16423.0% |
|